Ichor Medical Systems, Inc.

20 articles about Ichor Medical Systems, Inc.

• Ichor Medical Systems’ TriGrid® to be Used with a COVID-19 DNA Vaccine in Development by the Naval Medical Research Center

  4/27/2020

  Ichor Medical Systems, Inc. announced that its clinical stage TriGrid® Delivery System is being utilized for delivery of a DNA vaccine targeting the spike protein of SARS-CoV-2, the virus which causes coronavirus disease 2019, into non-human primates as part of a prime-boost vaccination strategy being developed by the Naval Medical Research Center.

• AbCellera Announces Partnership with NIAID Vaccine Research Center and Ichor Medical Systems to Tackle Pandemic Viral Outbreaks

  5/9/2019

  The AbCellera-led team will collaborate in an ambitious capability demonstration for the rapid generation of antibody-based countermeasures against a pandemic strain of influenza

• Ichor Medical Systems Announces Collaboration and Research License Agreement with AstraZeneca to Develop DNA-based Monoclonal Antibody Platform

  3/26/2019

  Ichor® Medical Systems, Inc. announced that it has entered into a collaboration and research license agreement with AstraZeneca for the development and clinical assessment of plasmid DNA constructs.

• Ichor Medical Systems Announces Utilization of Its Investigational TriGrid Delivery System in a Clinical Trial Evaluating GX-188E Vaccine Combined with a Checkpoint Inhibitor for Treatment of Cervical Cancer

  8/21/2018

  Ichor Medical Systems, Inc. (Ichor) announced today that its investigational TriGrid® Delivery System (TriGrid) is being utilized in a Phase 1b/2 clinical trial to administer GX-188E

• Ichor Medical Systems Announces First in Human Administration with Its Next Generation TriGrid System of a DNA Vaccine for Chronic Hepatitis B in Development

  6/4/2018

  Ichor Medical Systems, Inc. (Ichor) announced today the first in human dosing of JNJ-64300535 with its next generation investigational TriGrid® Delivery System.

• San Diego's Ichor Medical Forges a $85 Million Hep B Pact With Johnson & Johnson

  4/13/2015

• Ichor Medical Systems, Inc. Awarded DARPA Contract For Development Of TriGrid Platform For Passive Immunization

  11/17/2014

• Flextronics Partners With Ichor Medical Systems, Inc. To Provide Supply Chain Solutions, Including Design And Maunfacturing Services

  5/8/2014

• Ichor Medical Systems, Inc. Stikes Deal With Pfizer Inc. To Develop Electroporation Cancer Vaccine Devices

  2/5/2014

• US Department Of Defense Awards Grant to Ichor Medical Systems, Inc. to Evaluate Skin Electroporation Device tor Delivery of Multi-Agent Dna Vaccines

  4/18/2011

• Vaxonco, Inc.'s EP1300 Epitope-Based DNA Vaccine for Malaria Delivered by Ichor Medical Systems, Inc. TriGrid(TM) Electoporation Enters Phase I Trial

  9/23/2010

• Ichor Medical Systems, Inc. and Profectus BioSciences, Inc. Enter into an Agreement for Use of TriGrid(TM) Electroporation Device to Develop Multiple DNA Vaccines

  3/2/2010

• Ichor Medical Systems, Inc. Awarded $3.3 Million National Institutes of Health (NIH) Grant to Develop Alzheimer's Disease Vaccine

  8/5/2009

• Ichor Medical Systems, Inc. Melanoma Vaccine Clinical Trial Moves to Highest Dose Level

  3/4/2008

• Ichor Medical Systems, Inc.'s TriGrid Selected as Delivery Platform in Collaboration to Test Preventative HIV Vaccine

  10/1/2007

• Navy Partners with Ichor Medical Systems, Inc. to Develop a Vaccine for Anthrax and Plague

  8/6/2007

• FDA Approves Phase I Clinical Trial Using Ichor Medical Systems, Inc.'s TriGrid System and DNA Vaccine for Melanoma Developed at Sloan-Kettering

  5/14/2007

• Interferon Beta DNA Treatment Delivered with Ichor Medical Systems, Inc. Technology Reduces Atherosclerosis Progression in Mice

  3/27/2007

• United States Department of Defense Selects Ichor Medical Systems, Inc. to Develop Biodefense Vaccine

  3/12/2007

• RheoGene, Inc. Grants Ichor Medical Systems, Inc. A Commercial License To Develop A Regulated Gene Therapy For Multiple Sclerosis Using The RheoSwitch® Therapeutic System

  2/9/2006